NR2F1 and hepatocellular carcinoma: Our results found that NR2F1‐AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR‐363, providing a valuable therapeutic target for HCC tumorigenesis.